The manufacturer Takeda Pharma would partner with Hyderabad-based Biological E to make 50 million dengue vaccines.
Vaccine. (Representational image)
In a promising development in fight against mosquito-borne dengue infections, a dengue vaccine, Qdenga, also called TAK-003, developed by a Japanese firm — which will also be manufactured by a Hyderabad-based pharma company — has shown lasting effects and more than 50 percent efficacy. It is a live-attenuated vaccine, containing weakened versions of the four serotypes of the DENV virus.